Stock Track | Cytokinetics Soars 5.01% Pre-market on Positive Maple-HCM Trial Results for Aficamten

Stock Track

May 13, 2025

Shares of Cytokinetics Inc (CYTK) surged 5.01% in pre-market trading on Tuesday, following the announcement of positive topline results from its Maple-HCM trial for aficamten, a potential treatment for hypertrophic cardiomyopathy (HCM).

The company reported that the Maple-HCM study met its primary endpoint, demonstrating a favorable safety profile for aficamten compared to metoprolol, a commonly used beta-blocker for HCM treatment. This positive outcome could potentially position aficamten as a promising alternative for HCM patients.

Investors are likely encouraged by these results, especially considering that aficamten is currently under FDA review with a PDUFA date set for December 26, 2025. The positive trial results may bolster the drug's chances for approval, potentially opening up a significant market opportunity for Cytokinetics in the treatment of HCM. As the market digests this news, the stock's movement reflects growing optimism about the company's future prospects in the cardiovascular disease space.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1174537530"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1174537530\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1174537530?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-05-13 19:32","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1174537530","market":"us","top_or_hot":-1,"title":"Stock Track | Cytokinetics Soars 5.01% Pre-market on Positive Maple-HCM Trial Results for Aficamten","media":"Stock Track","content":"<p>Shares of Cytokinetics Inc (CYTK) surged 5.01% in pre-market trading on Tuesday, following the announcement of positive topline results from its Maple-HCM trial for aficamten, a potential treatment for hypertrophic cardiomyopathy (HCM).</p>\n\n<p>The company reported that the Maple-HCM study met its primary endpoint, demonstrating a favorable safety profile for aficamten compared to metoprolol, a commonly used beta-blocker for HCM treatment. This positive outcome could potentially position aficamten as a promising alternative for HCM patients.</p>\n\n<p>Investors are likely encouraged by these results, especially considering that aficamten is currently under FDA review with a PDUFA date set for December 26, 2025. The positive trial results may bolster the drug's chances for approval, potentially opening up a significant market opportunity for Cytokinetics in the treatment of HCM. As the market digests this news, the stock's movement reflects growing optimism about the company's future prospects in the cardiovascular disease space.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Cytokinetics Soars 5.01% Pre-market on Positive Maple-HCM Trial Results for Aficamten</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Cytokinetics Soars 5.01% Pre-market on Positive Maple-HCM Trial Results for Aficamten\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-05-13 19:32</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shares of Cytokinetics Inc (CYTK) surged 5.01% in pre-market trading on Tuesday, following the announcement of positive topline results from its Maple-HCM trial for aficamten, a potential treatment for hypertrophic cardiomyopathy (HCM).</p>\n\n<p>The company reported that the Maple-HCM study met its primary endpoint, demonstrating a favorable safety profile for aficamten compared to metoprolol, a commonly used beta-blocker for HCM treatment. This positive outcome could potentially position aficamten as a promising alternative for HCM patients.</p>\n\n<p>Investors are likely encouraged by these results, especially considering that aficamten is currently under FDA review with a PDUFA date set for December 26, 2025. The positive trial results may bolster the drug's chances for approval, potentially opening up a significant market opportunity for Cytokinetics in the treatment of HCM. As the market digests this news, the stock's movement reflects growing optimism about the company's future prospects in the cardiovascular disease space.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CYTK","symbol_name":"Cytokinetics","start_time":0,"source_url":"","article_id":"1174537530","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1174537530","pubTimestamp":1747135940,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Shares of Cytokinetics Inc  surged 5.01% in pre-market trading on Tuesday, following the announcement of positive topline results from its Maple-HCM trial for aficamten, a potential treatment for hypertrophic cardiomyopathy .The company reported that the Maple-HCM study met its primary endpoint, demonstrating a favorable safety profile for aficamten compared to metoprolol, a commonly used beta-blocker for HCM treatment. This positive outcome could potentially position aficamten as a promising al","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"CYTK":"Cytokinetics"},"translate_title":"Aficamten的Maple-HCM试验结果呈阳性，股票跟踪Cytokinetics盘前飙升5.01%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CYTK":1},"content_text":"Shares of Cytokinetics Inc (CYTK) surged 5.01% in pre-market trading on Tuesday, following the announcement of positive topline results from its Maple-HCM trial for aficamten, a potential treatment for hypertrophic cardiomyopathy (HCM).\nThe company reported that the Maple-HCM study met its primary endpoint, demonstrating a favorable safety profile for aficamten compared to metoprolol, a commonly used beta-blocker for HCM treatment. This positive outcome could potentially position aficamten as a promising alternative for HCM patients.\nInvestors are likely encouraged by these results, especially considering that aficamten is currently under FDA review with a PDUFA date set for December 26, 2025. The positive trial results may bolster the drug's chances for approval, potentially opening up a significant market opportunity for Cytokinetics in the treatment of HCM. As the market digests this news, the stock's movement reflects growing optimism about the company's future prospects in the cardiovascular disease space.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}